Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200044 | 0.82 | MAPK1 (0.64) | L3MBTL1MAPK1SMN1; SMN2KDM1ACHRM4 | |
| SCHEMBL5197966 | 0.76 | GAA (0.46) | L3MBTL1SMN1; SMN2MEN1KMT2ANOS2 | |
| SCHEMBL14430365 | 0.75 | ALDH1A1 (0.44) | L3MBTL1BRD4MEN1KMT2AKDM4E | |
| SCHEMBL14430479 | 0.74 | MAPK1 (0.61) | L3MBTL1MAPK1SMN1; SMN2KDM1ACHRM4 | |
| SCHEMBL12084621 | 0.74 | SIGMAR1 (0.63) | KCNH2CHRM4 | |
| SCHEMBL14430492 | 0.73 | MAPK1 (0.44) | MAPK1SMN1; SMN2KDM1AALDH1A1 | |
| SCHEMBL14430488 | 0.72 | MAPK1 (0.58) | L3MBTL1MAPK1SMN1; SMN2KDM1ACHRM4 | |
| SCHEMBL13000316 | 0.72 | SIGMAR1 (0.49) | L3MBTL1SMN1; SMN2MEN1KMT2AKCNH2 | |
| SCHEMBL11336125 | 0.70 | L3MBTL1 (0.46) | L3MBTL1BRD4MEN1KMT2ANOS2 | |
| SCHEMBL4939597 | 0.70 | APP (0.47) | L3MBTL1APPKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | L3MBTL1 2143/4885MAPK1 664/4885SMN1; SMN2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.